Interferon-beta enhances sensitivity to gemcitabine in pancreatic cancer

BACKGROUND: Adjuvant gemcitabine for pancreatic cancer has limited efficacy in the clinical setting. Impaired drug metabolism is associated with treatment resistance. We aimed to evaluate the chemosensitising effect of interferon-beta (IFN-β). METHODS: BxPC-3, CFPAC-1, and Panc-1 cells were pre-trea...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:BMC Cancer
Autores principales: Blaauboer, Amber, Booy, Stephanie, van Koetsveld, Peter M., Karels, Bas, Dogan, Fadime, van Zwienen, Suzanne, van Eijck, Casper H. J., Hofland, Leo J.
Formato: Artigo
Lenguaje:Inglês
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7513525/
https://ncbi.nlm.nih.gov/pubmed/32967656
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-020-07420-0
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares